PSMA PET-CT in the Diagnosis and Staging of Prostate Cancer

Alexander D Combes; Catalina A Palma; Ross Calopedos; Lingfeng Wen; Henry Woo; Michael Fulham; Scott Leslie

doi:10.3390/diagnostics12112594

PSMA PET-CT in the Diagnosis and Staging of Prostate Cancer

Diagnostics (Basel). 2022 Oct 26;12(11):2594. doi: 10.3390/diagnostics12112594.

Authors

Alexander D Combes¹, Catalina A Palma¹, Ross Calopedos¹, Lingfeng Wen^{2

3}, Henry Woo^{4

5}, Michael Fulham^{2

4}, Scott Leslie^{1

4

5

6}

Affiliations

¹ Department of Urology, Royal Prince Alfred Hospital, Sydney, NSW 2050, Australia.
² Department of Molecular Imaging, Royal Prince Alfred Hospital, Sydney, NSW 2050, Australia.
³ Faculty of Engineering and Computer Science, University of Sydney, Sydney, NSW 2006, Australia.
⁴ Faculty of Medicine, University of Sydney, Sydney, NSW 2006, Australia.
⁵ Department of Urology, Chris O'Brien Lifehouse, Sydney, NSW 2050, Australia.
⁶ RPA Institute of Academic Surgery, Sydney, NSW 2050, Australia.

Abstract

Prostate cancer is the most common cancer and the second leading cause of cancer death in men. The imaging assessment and treatment of prostate cancer has vastly improved over the past decade. The introduction of PSMA PET-CT has improved the detection of loco-regional and metastatic disease. PSMA PET-CT also has a role in the primary diagnosis and staging, in detecting biochemical recurrence after curative treatment and in metastasis-directed therapy. In this paper we review the role of PSMA PET-CT in prostate cancer.

Keywords: PSMA PET; imaging; prostate cancer.

Publication types

Review

Grants and funding

This research received no external funding.